Solid Tumor Malignancies Clinical Trials

19 recruiting

Solid Tumor Malignancies Trials at a Glance

26 actively recruiting trials for solid tumor malignancies are listed on ClinicalTrialsFinder across 6 cities in 6 countries. The largest study group is Phase 1 with 19 trials, with the heaviest enrollment activity in Fairfax, Houston, and San Antonio. Lead sponsors running solid tumor malignancies studies include Kumquat Biosciences Inc., VelaVigo Bio Inc, and First Ascent Biomedical Inc..

Browse solid tumor malignancies trials by phase

Treatments under study

About Solid Tumor Malignancies Clinical Trials

Looking for clinical trials for Solid Tumor Malignancies? There are currently 19 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Solid Tumor Malignancies trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Solid Tumor Malignancies clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 26 trials

Recruiting
Phase 1

A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

Solid Tumor MalignanciesCRC (Colorectal Cancer)KRAS G12C Mutation+1 more
Kumquat Biosciences Inc.140 enrolled11 locationsNCT06720987
Recruiting
Phase 1Phase 2

First-in-Human Trial of VBC101 in Participants With Advanced Solid Tumor Malignancies

Participants With Advanced Solid Tumor Malignancies
VelaVigo Bio Inc310 enrolled5 locationsNCT07136779
Recruiting
Phase 1Phase 2

Clinical Trial of VBC103 in Patients With Advanced Malignant Solid Tumors

Participants With Advanced Solid Tumor Malignancies
VelaVigo Bio Inc255 enrolled1 locationNCT07299747
Recruiting
Phase 2

Efficacy and Safety of the Valemetostat in Patients With Selected Solid Tumors.

Ovarian CancerSolid Tumor MalignanciesClear Cell Endometrial Carcinoma
Gustave Roussy, Cancer Campus, Grand Paris900 enrolled4 locationsNCT07303387
Recruiting
Phase 1

Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Solid Tumor MalignanciesEGFREGFR Positive Solid Tumors
Vir Biotechnology, Inc.450 enrolled4 locationsNCT06960395
Recruiting
Phase 4

Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

CholangiocarcinomaSolid Tumor MalignanciesGlioma+1 more
Rigel Pharmaceuticals16 enrolled2 locationsNCT07486713
Recruiting
Phase 1

Phase I Study of the Safety, Tolerability, and Efficacy of an Engineered Mitochondrial Vaccine in Advanced Solid Tumors

Advanced Solid MalignanciesAdvanced Solid Tumor Malignancies
West China Hospital12 enrolled1 locationNCT06927297
Recruiting
Not Applicable

CSF and Blood Plasma Liquid Biopsy in Patients With Metastatic Solid Tumours and CNS Metastases or no CNS Metastases

Brain MetastasasesSolid Tumor MalignanciesLeptomeningeal Disease (LMD)
Sunnybrook Health Sciences Centre60 enrolled1 locationNCT07476781
Recruiting
Phase 1

A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies

Solid Tumor Malignancies
Kumquat Biosciences Inc.78 enrolled12 locationsNCT07207707
Recruiting
Phase 1

A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

Solid Tumor Malignancies
Kumquat Biosciences Inc.84 enrolled15 locationsNCT06994806
Recruiting
Phase 1Phase 2

Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors

Colorectal CarcinomaBladder CancerSolid Tumor Malignancies+2 more
Tasca Therapeutics150 enrolled13 locationsNCT07030257
Recruiting
Phase 1

A Study of SH009 Injection in Patients With Advanced Solid Tumors.

Esophageal CancerBreast Cancer (Locally Advanced or Metastatic)Lung Cancer (NSCLC)+4 more
Nanjing Sanhome Pharmaceutical, Co., Ltd.150 enrolled1 locationNCT07390838
Recruiting
Phase 1

A Phase I First-in-Human Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of SWA1211 Tablets in Subjects With Advanced Solid Tumors

Solid Tumor Malignancies
Beijing StoneWise Technology Co., Ltd60 enrolled1 locationNCT07363967
Recruiting
Phase 1Phase 2

NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies

Advanced or Metastatic Solid Tumor Malignancies
Novita Pharmaceuticals, Inc.140 enrolled18 locationsNCT05023486
Recruiting
Phase 1

A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors

Esophageal CancerProstate CancerLung Cancer (NSCLC)+1 more
Phrontline Biopharma200 enrolled7 locationsNCT07181473
Recruiting
Not Applicable

xDRIVE for Florida-based Cancer Patients

CancerLeukaemiaLymphoma+5 more
First Ascent Biomedical Inc.210 enrolled2 locationsNCT07167381
Recruiting
Phase 1

A Clinical Study of GO306 in Patients With Advanced Solid Tumors

Solid Tumor Malignancies
GeneSail Biotech (Shanghai) Co., Ltd.32 enrolled6 locationsNCT07128914
Recruiting
Phase 1

A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of SXRN Injection in Patients With Cancer Cachexia

Solid Tumor MalignanciesCachexia-Anorexia Syndrome
Jiangsu Nutai Biologics Co., Ltd54 enrolled1 locationNCT07231120
Recruiting
Phase 3

Trial to Evaluate irAEs With Different Standard of Care Dosing Strategies of Standard of Care Immunotherapies

Solid Tumor Malignancies
University of Kansas Medical Center192 enrolled1 locationNCT07174453
Recruiting
Phase 2

A Single-arm Clinical Trial Using Patient-derived Tumor Tissue Fragment Models for Drug Sensitivity Testing to Guide Treatment in Previously Treated Cancers

Solid Tumor CancerSolid Tumor Malignancies
Qilu Hospital of Shandong University35 enrolled1 locationNCT07264803